PTPRC and neoplasm: In the second in vivo test to confirm the anti-tumor ability of 2A5, 11C9 and 41D12 CAR-T cells, we measured the absolute number of circulating CD45 + CD3 + human cells every week post cells infusion, 11C9 CAR-T cells induced highest T cells expansion than the other CD70 CAR-T cells at the first expansive peak in day 14, and in day 70 (day 7 after ACHN re-challenge), there was an obvious expansion of T cells observed (Fig. 4D).